A Trial to Evaluate an HIV Vaccine, N332-GT5 gp140, in Adult Participants Without
HIV
Research Question:
Is the vaccine, N322-GT5 gp140 safe in adults without HIV and does it induce an immune
response?
Basic Study Information
Purpose:
Finding a vaccine against HIV remains a top priority for public health. This study,
called HVTN 144, is an early step in the process. It's like testing the first pieces
of a puzzle before building the whole picture.
The goal is to see if a new HIV vaccine candidate is safe and can trigger the right
immune response in people without HIV. The vaccine candidate itself is a protein called
N332-GT5 gp140, combined with a special booster called SMNP.
The study will involve two parts:
Part 1: 84 healthy adults between 18 and 55 years old will receive the vaccine candidate
at different doses and schedules. This helps find the safest and most effective way
to give the vaccine.
Part 2: The best dose and schedule from Part 1 will be used to see how well the vaccine
triggers the desired immune response, specifically a certain type of antibody called
BG18-class IgG.
The whole study will take about 22 months. Most of that time is for safety monitoring
and follow-up after the last vaccination.
Location: University of Rochester Medical Center
Study Reference #: STUDY00008618
Lead Researcher (Principal Investigator)
Lead Researcher:
Michael Keefer
Study Contact Information
Study Coordinator: Michael Keefer, MD
Phone: (585) 275-5871
Email: michael_keefer@urmc.rochester.edu
Additional Study Details
Reimbursement:
Yes
Trial Not Found
The study you are looking for is not active at this time.
Return to Search